MK-6884
Total Payments
$211,301
Transactions
14
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $142,250 | 4 | 0 |
| 2017 | $69,051 | 10 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $211,301 | 14 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Three-Part Trial to Qualify 11CMK-6884 Positron Emission Tomography for Use as a Biomarker for Regional M4 Receptor Density Quantification in the Human Brain | Merck Sharp & Dohme Corporation | $211,301 | 0 |
Top Doctors Receiving Payments for MK-6884
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $211,301 | 14 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $211,301
Product Information
- Type Drug
- Total Payments $211,301
- Total Doctors 0
- Transactions 14
About MK-6884
MK-6884 is a drug associated with $211,301 in payments to 0 healthcare providers, recorded across 14 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $142,250 was paid across 4 transactions to 0 doctors.
The most common payment nature for MK-6884 is "Unspecified" ($211,301, 100.0% of total).
MK-6884 is associated with 1 research study, including "A Three-Part Trial to Qualify 11CMK-6884 Positron Emission Tomography for Use as a Biomarker for Regional M4 Receptor Density Quantification in the Human Brain" ($211,301).